Beneficial effects of statins in coronary artery disease - Beyond lowering cholesterol

Annals of Pharmacotherapy

Volumn 34, Issue 12, 2000, Pages 1432-1439

  Sotiriou, Christopher G ^a,b   Cheng, Judy WM ^a,c  

^a LONG ISLAND UNIVERSITY   (United States)

^b Broadway Pharmacy   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Antithrombotic effects; Endothelial function; Plaque stabilization; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; ENALAPRIL; FIBRINOGEN; FIBRINOLYTIC FACTOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A; LISINOPRIL; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; SIMVASTATIN; THROMBOPLASTIN;

ATHEROSCLEROTIC PLAQUE; CELL GROWTH; CORONARY ARTERY DISEASE; FIBRINOLYSIS; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULAR ENDOTHELIUM;

BLOOD COAGULATION; BLOOD PLATELETS; BLOOD PRESSURE; BLOOD VISCOSITY; CHOLESTEROL; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MUSCLE, SMOOTH; PRAVASTATIN; SIMVASTATIN;

EID: 0033638209     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10124     Document Type: Review

References (81)

1. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
2. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS)
3. Effects of monotherapy with HMG Co-A reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial
4. Effect of simvastatin on coronary atheroma: The Multicenter Anti-Atheroma Study (MAAS)
5. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)
6. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
8. Prevention of coronary heart disease with pravastatin in patients with hypercholesterolemia
9. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol events
10. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S)
11. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
12. The emerging concept of vascular remodeling
13. Atherosclerosis: An update
14. Endothelium mediated coronary blood flow modulation in humans: Effects of age, atherosclerosis, hypercholesterolemia, and hypertension
15. Pathophysiology of atherosclerosis
16. Antioxidants and atherosclerotic heart disease
17. Atherosclerosis: Basic mechanisms oxidation, inflammation, and genetics
18. Unmet therapeutic needs in the management of acute ischemics
19. Advancing the battle against acute ischemic syndromes: A focus on the GP IIb-IIIa inhibitors
20. Role of platelet-inhibitor agents in coronary artery disease
21. Thrombosis and the pharmacology of antithrombotic agents
22. The pathogenesis of coronary artery disease and the acute coronary syndrome
23. Molecular and cellular biology of blood coagulation
24. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and huridin
25. Relation between coronary artery stenosis assessed by visual, caliper, and computer methods and exercise capacity in patients with single vessel coronary artery disease
26. Angiographic progression of coronary artery disease and the development of myocardial infarction
27. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris
28. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease
29. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease
30. Effects of short-term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia
31. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol level
32. Clinical outcomes in statin treatment trials
33. Cholesterol reduction and the risk for stroke in men: A meta-analysis of randomized controlled trials
34. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients
35. Cholesterol lowering and endothelial function
36. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
37. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
38. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
39. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
40. Increased bioavailability of nitric oxide after lipid lowering therapy in hypercholesterolemic patients
41. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial
42. The mechanism of improvement in endothelial function by pravastatin: Direct effect or through cholesterol lowering
43. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension
44. Coronary plaque disruption
45. Statins do more than just lowering cholesterol
46. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: In vitro and in vivo studies
47. Pravastatin therapy in hyperlipidemia effects on thrombus formation and the systemic hemostatic profile
48. Importance of endothelial function in mediating the benefits of lipid-lowering therapy
49. The Kuopio Atherosclerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression
50. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages
51. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: In vitro and ex vivo studies
52. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies
53. Effective lovastatin therapy in elderly hypercholesterolemic patients - An antioxidative impact?
54. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
55. Vastatins inhibit cholesterol ester accumulation in human monocyte - Derived macrophages
56. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression
57. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types
58. Direct effects of statins on the vascular wall
59. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth
60. Assessment of effects of lipid-lowering drugs on hemostasis
61. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
62. Effects of long-term treatment with lovastatin on the clotting system and blood platelets
63. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients
64. Antiatherothrombotic properties of statins
65. Treatment with hydroxymethylglutaryl coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system
66. Effect of atorvastatin on plasma fibrinogen
67. Atorvastatin: An effective agent in familial hypercholesterolemia
68. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
69. Atorvastatin for the management of type 2 diabetic patients with dyslipidemia. A mid-term (9 months) treatment experience
70. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia
71. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia
72. Long-term effects of pravastatin on plasma concentration of C reactive protein
73. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels
74. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease
75. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids
76. Effects of one year of treatment with pravastatin, an HMG-CoA
77. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin
78. Lovastatin alters blood rheology in primary hyperlipoproteinemia: Dependence on lipoprotein (a)?
79. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia
80. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)
81. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease